Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis

Cao, Zhiqiang; Zhu, Xia; Yang, Qinbo; Xu, Qingqing; Zhang, Chunhong

doi:10.1080/0886022x.2022.2073893

Cited by 3 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 A case of FSGS without Ig deposition whose psoriasis and nephropathy regressed with secukinumab was reported in the literature. 7 The other reported case developed IgAN in the 5th month of secukinumab treatment, and proteinuria improved after tonsillectomy and pulse steroid therapy without discontinuation of treatment. The authors attributed the nephropathy to obesity and metabolic syndrome developed due to lifestyle changes of the patient, not due to secukinumab because proteinuria regressed despite continued treatment.…”

Section: Correspondence E36mentioning

confidence: 89%

See 1 more Smart Citation

A case of psoriasis with IgA nephropathy successfully treated with secukinumab

Kulaklı,

Akagün

2023

Int J Dermatology

View full text Add to dashboard Cite

amount of alcohol consumption or an effect on MF-specific survival. Consequently, it is unlikely that alcohol consumption confers a true protective benefit in MF progression. Comorbidities, including hypertension, hyperlipidemia, diabetes, obesity, solid tumor cancer, leukemia or lymphoma, autoimmune disease, and smoking, did not affect PFS in MF patients from our cohort. While heart disease was associated with shorter PFS on univariate analysis, this association disappeared with multivariate modeling.This study provides further information on potential factors that are associated with disease progression in MF. While the presence of various comorbidities did not exhibit a significant association with MF PFS or mortality, clinicians should continue to monitor these factors as they could impact the overall health and quality of life of the patients. Furthermore, patients can be reassured that these comorbidities are not associated with the progression of MF.Although this is a large MF cohort with comprehensive chart review, patients who receive primary care outside our system may not have had complete medical and social histories fully documented in their chart, potentially limiting our ability to detect more subtle associations with PFS. Future studies are needed to determine if other factors, such as exposure to environmental carcinogens, affect MF incidence or PFS.

show abstract

Section: Correspondence E36mentioning

confidence: 89%

“…Therefore, IL-17 blocking can be an effective agent in the treatment of IgAN. 7,8 The effectiveness and safety of secukinumab in psoriasis with IgAN require confirmation by long-term follow-up studies of more patients. Our successful treatment of a patient provides a reference for the future treatment of such patients.…”

Section: Correspondence E36mentioning

confidence: 99%

A case of psoriasis with IgA nephropathy successfully treated with secukinumab

Kulaklı,

Akagün

2023

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…Secukinumab is a monoclonal antibody (IgG1 kappa) that suppresses the pro-inflammatory cytokine IL-17A, which is involved in the onset of several autoimmune diseases, such as psoriasis, ankylosing spondylitis, and psoriatic arthritis (Toussirot 2012 ). The molecular weight of secukinumab is about 151 kilodaltons, composed of two identical heavy chains and two identical light chains (Cao et al 2022 ). They prevent IL-17A from binding to its receptor on immune cells through selective binding to its attachment site, lowering inflammation and its associated effects (Patrikiou et al 2020 ).…”

Section: Il-17 Inhibitors and Risk Of Candidiasismentioning

confidence: 99%

Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management

Bilal,

Khan,

Khan

et al. 2023

Mycology

View full text Add to dashboard Cite

The application of interleukin-17 (IL-17) inhibitors, including secukinumab, ixekizumab, brodalumab, and bimekizumab, are associated with elevated risk of candidiasis. These medications interfere with the IL-17 pathway, which is essential for maintaining mucosal barriers and coordinating the immune response against Candida species. The observational data and clinical trials demonstrate the increased incidence of candidiasis in individuals treated with IL-17 inhibitors. Brodalumab and bimekizumab pose a greater risk than secukinumab in eliciting candidiasis, whereas the data regarding ixekizumab are equivocal. Higher doses and prolonged treatment duration of IL-17 inhibitors increase the risk of candidiasis by compromising the immune response against Candida species. Prior to prescribing IL-17 inhibitors, healthcare professionals should comprehensively evaluate patients’ medical histories and assess their risk factors. Patients should be educated on the signs and symptoms of candidiasis to facilitate early detection and intervention. Future research should focus on identifying the risk factors associated with candidiasis in patients receiving IL-17 inhibitors. Prospective studies and long-term surveillance are required to explore the impact of specific inhibitors on the incidence and severity of candidiasis and to evaluate the effectiveness of combination therapies, such as concurrent use of IL-17 inhibitors and prophylactic antifungal agents.

show abstract